Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.05M | $-50.22M | $-1.65 |
| 2024 | $1.88M | $-60.66M | $-4.66 |
| 2023 | $1.50M | $-27.78M | $-3.75 |
| 2022 | $958.0K | $-73.44M | $-13.26 |
| 2021 | $7.73M | $-64.10M | $-14.42 |
Social Signal Score
Earnings
Typical surprise -23.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 6$-0.30 vs $-0.24miss
- Mon, May 12$-0.26 vs $-0.24miss
- Mon, Mar 24$0.48 vs $-0.43beat
- Tue, Nov 12$-0.98 vs $-0.44miss
- Thu, Aug 8$-0.36 vs $-0.56beat
- Wed, May 15$-1.13 vs $-0.67miss
Estimates and results for OCX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
OCXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsmarketbeat.com·4d ago·Negative
Oncocyte Q2 Earnings Call Highlights Oncocyte NASDAQ: IMDX executives said they continue to target FDA marketing authorization for the GraftAssureDx kidney-transplant rejection test later this year, while preparing for a commercial launch and managing spending ahead of expected revenue growth.
View source ↗